{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:22:50Z","timestamp":1789906970216,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":257,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.radonc.2012.09.018","type":"journal-article","created":{"date-parts":[[2012,11,3]],"date-time":"2012-11-03T03:31:25Z","timestamp":1351913485000},"page":"184-192","source":"Crossref","is-referenced-by-count":37,"title":["Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer"],"prefix":"10.1016","volume":"105","clinical-trial-number":[{"clinical-trial-number":"nct00193856","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"James W.","family":"Denham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantelle","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel A.","family":"Spry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Duchesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizbeth","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keen-Hun","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirdosh Kumar","family":"Gogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Delahunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McElduff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2012.09.018_b0005","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.juro.2006.03.092","article-title":"Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone","volume":"176","author":"Granfors","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2012.09.018_b0010","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.09.018_b0015","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.09.018_b0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2012.09.018_b0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2012.09.018_b0030","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","article-title":"Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial","volume":"6","author":"Denham","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0035","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2012.09.018_b0040","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/pcan.2009.35","article-title":"Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer","volume":"12","author":"Freedland","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.radonc.2012.09.018_b0050","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1046\/j.1464-410X.1997.00234.x","article-title":"Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade","volume":"79","author":"Strum","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.radonc.2012.09.018_b0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/pcan.2008.51","article-title":"Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation","volume":"12","author":"Galvao","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.radonc.2012.09.018_b0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2012.09.018_b0065","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0070","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0075","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2012.09.018_b0080","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0305-7372(02)00095-6","article-title":"The anti-tumour activity of bisphosphonates","volume":"28","author":"Neville-Webbe","year":"2002","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2012.09.018_b0085","first-page":"3890","article-title":"Bisphosphates inhibit prostate and breast carcinoma cell adhesion to unmineralised and mineralised bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2012.09.018_b0090","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2012.09.018_b0095","unstructured":"TROG 03.04 RADAR trial \u2013 randomised androgen deprivation and radiotherapy, <http:\/\/clinicaltrials.gov\/ct\/show\/NCT00193856?order=5>; 2005."},{"key":"10.1016\/j.radonc.2012.09.018_b0100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.radonc.2008.10.011","article-title":"Assuring high quality treatment delivery in clinical trials \u2013 results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 \u201cRADAR\u201d set-up accuracy study","volume":"90","author":"Haworth","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0105","unstructured":"Denham JW, Nowitz M, Joseph D, et al. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the TROG 03.04 RADAR trial for locally advanced prostate cancer. University of Newcastle; 2012. Unpublished."},{"key":"10.1016\/j.radonc.2012.09.018_b0110","unstructured":"Denham JW, Wilcox C, Joseph D, et al. Quality of life in the TROG 03.04 RADAR randomised controlled trial for locally advanced prostate cancer. Lancet Oncol, in press."},{"key":"10.1016\/j.radonc.2012.09.018_b0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1754-9485.2009.02047.x","article-title":"Comprehensive Australasian multicentre dosimetric intercomparison: issues, logistics and recommendations","volume":"53","author":"Ebert","year":"2009","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0120","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1118\/1.3626484","article-title":"Dosimetric intercomparison for multicentre clinical trials using a patient-based anatomic pelvic phantom","volume":"38","author":"Ebert","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2012.09.018_b0125","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1118\/1.3626573","article-title":"Design, manufacture, and evaluation of an anthropomorphic pelvic phantom purpose-built for radiotherapy dosimetric intercomparison","volume":"38","author":"Harrison","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2012.09.018_b0130","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.radonc.2007.11.013","article-title":"Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system","volume":"86","author":"Ebert","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0135","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0360-3016(95)90159-0","article-title":"LENT SOMA scales for all anatomic sites","volume":"31","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.09.018_b0140","doi-asserted-by":"crossref","first-page":"N337","DOI":"10.1088\/0031-9155\/55\/11\/N04","article-title":"Comparison of DVH data from multiple radiotherapy treatment planning systems","volume":"55","author":"Ebert","year":"2010","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2012.09.018_b0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.radonc.2005.10.005","article-title":"Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation","volume":"77","author":"Christie","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0150","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.ijrobp.2007.07.2354","article-title":"Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: Preliminary results of a multicenter prospective study","volume":"70","author":"Fiorino","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.09.018_b0155","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2009.02.025","article-title":"Dose\u2013volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397","volume":"76","author":"Gulliford","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.09.018_b0160","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.radonc.2008.09.019","article-title":"Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial","volume":"90","author":"Capp","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0165","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1470-2045(07)70341-8","article-title":"Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients","volume":"8","author":"Andreyev","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/gutjnl-2011-300563","article-title":"Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer","volume":"61","author":"Andreyev","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.radonc.2012.09.018_b0175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijrobp.2009.10.071","article-title":"A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial","volume":"79","author":"Lamb","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2012.09.018_b0180","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.radonc.2011.01.006","article-title":"Does the planning dose\u2013volume histogram represent treatment doses in image-guided prostate radiation therapy? Assessment with cone-beam computerised tomography scans","volume":"98","author":"Hatton","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0185","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2008.11.013","article-title":"Urethral stricture following high dose rate brachytherapy for prostate cancer","volume":"91","author":"Sullivan","year":"2009","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2012.09.018_b0190","unstructured":"Zamboglou N, Tselis N, Baltas D, et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: Treatment evaluation and mature results. Int J Radiat Oncol Biol Phys, in press."},{"key":"10.1016\/j.radonc.2012.09.018_b0195","doi-asserted-by":"crossref","unstructured":"Singh J, Greer PB, White MA, et al. Treatment related morbidity in prostate cancer: a comparison of 3DCRT with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys, http:\/\/dx.doi.org\/10.1016\/j.ijrobp.2012.07.2376.","DOI":"10.1016\/j.ijrobp.2012.07.2376"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814012004434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814012004434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T15:29:17Z","timestamp":1540135757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814012004434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0167814012004434"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2012.09.018","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}